Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A neuroendocrine carcinoma of the prostate gland with unfavorable prognosis, composed of small cells containing neurosecretory granules. Approximately half of the cases show a mixture of small cells and adenocarcinoma cells.
Biomarker and diagnostic research for prostate small cell carcinoma has been reported in the published literature.
6 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, biologic therapy, procedural interventions, and other interventions. Pipeline includes 5 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05969860](https://clinicaltrials.gov/study/NCT05969860) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 1:09 PM UTC
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer |
PHASE2 |
Mayo Clinic |
RECRUITING |
[NCT04471974](https://clinicaltrials.gov/study/NCT04471974) | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | PHASE2 | Rahul Aggarwal | UNKNOWN |
[NCT03582475](https://clinicaltrials.gov/study/NCT03582475) | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | PHASE1 | Jonsson Comprehensive Cancer Center | UNKNOWN |
[NCT05691465](https://clinicaltrials.gov/study/NCT05691465) | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | PHASE2 | National Cancer Institute (NCI) | UNKNOWN |
[NCT04592237](https://clinicaltrials.gov/study/NCT04592237) | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | PHASE2 | M.D. Anderson Cancer Center | ACTIVE_NOT_RECRUITING |
117 publications have been identified in PubMed for prostate small cell carcinoma. Research spans Review / Meta-Analysis (31%), Basic Science / Preclinical (26%), and Epidemiology / Natural History (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 36 | 31% |
Laboratory research | 30 | 26% |
Disease patterns and progression | 14 | 12% |
Clinical study results | 13 | 11% |
Testing and diagnosis research | 9 | 8% |
Patient case studies | 9 | 8% |
New treatment approaches | 6 | 5% |
Liv T (2026). [PMID: 41395640](https://pubmed.ncbi.nlm.nih.gov/41395640/). *Histopathology*. [Review / Meta-Analysis]
Al-Khanaty A (2026). [PMID: 41595117](https://pubmed.ncbi.nlm.nih.gov/41595117/). *Cancers*. [Review / Meta-Analysis]
Sklinda K (2026). [PMID: 41827718](https://pubmed.ncbi.nlm.nih.gov/41827718/). *Cancers*. [Review / Meta-Analysis]
Zhang B (2026). [PMID: 41469155](https://pubmed.ncbi.nlm.nih.gov/41469155/). *J Nucl Med*. [Diagnostic / Biomarker]
Vlachostergios PJ (2026). [PMID: 41804968](https://pubmed.ncbi.nlm.nih.gov/41804968/). *Immunotherapy*. [Review / Meta-Analysis]
Okoye E (2026). [PMID: 32966007](https://pubmed.ncbi.nlm.nih.gov/32966007/). *Unknown Journal*. [Basic Science / Preclinical]
Harrs CF (2026). [PMID: 41384686](https://pubmed.ncbi.nlm.nih.gov/41384686/). *Histopathology*. [Review / Meta-Analysis]
Hao X (2025). [PMID: 40444064](https://pubmed.ncbi.nlm.nih.gov/40444064/). *Dose-response : a publication of International Hormesis Society*. [Review / Meta-Analysis]
Wei W (2025). [PMID: 39891747](https://pubmed.ncbi.nlm.nih.gov/39891747/). *European journal of nutrition*. [Epidemiology / Natural History]
Ortiz-Hernández GL (2025). [PMID: 41009559](https://pubmed.ncbi.nlm.nih.gov/41009559/). *International journal of molecular sciences*. [Basic Science / Preclinical]